CLAIMS

1. Use of a compound selected from the group consisting of elafibranor, GFT1007, and a pharmaceutically acceptable salt of elafibranor or GFT1007, for the manufacture of a pharmaceutical composition reducing fatigue in a subject having primary biliary cholangitis (PBC).

2. Use of a compound selected from the group consisting of elafibranor, GFT1007, and a pharmaceutically acceptable salt of elafibranor or GFT1007, for the manufacture of a pharmaceutical composition for reducing fatigue associated to PBC in a subject having PBC.

3. Use according to claim 1 or 2, wherein the subject having PBC has also pruritus.

4. Use of a compound selected from the group consisting of elafibranor, GFT1007, and a pharmaceutically acceptable salt of elafibranor or GFT1007, for the manufacture of a pharmaceutical composition for treating PBC in a subject having PBC with fatigue, without provoking and/or worsening the fatigue of said subject.

5. Use according to any one of claims 1 to 4, wherein the PROMIS Fatigue T-score is reduced by at least 1 point from baseline in a subject having PBC.

6. Use according to any one of claims 1 to 5, wherein the PROMIS Fatigue T-score is reduced by at least 2 points from baseline in a subject having PBC and pruritus.

7. Use according to any one of claims 1 to 6, wherein the compound comprises elafibranor or a pharmaceutically acceptable salt thereof.

8. Use according to any one of claims 1 to 7, wherein the compound comprises elafibranor.

9. Use according to any one of claims 1 to 8, wherein the pharmaceutical composition is in a form selected from the group consisting of a gel, an oil, a pill, a tablet, a powder, a gel cap, a capsule, and a galenic form or device assuring a prolonged and/or slow release.

10. Use according to any one of claims 1 to 9, wherein the pharmaceutical composition is to be administered once a day.

11. Use according to any one of claims 1 to 10, wherein the pharmaceutical composition is to be administered orally.

12. Use according to any one of claims 1 to 11, wherein elafibranor, GFT1007, or a pharmaceutically acceptable salt of elafibranor or of GFT1007 is to be administered at a dose of 80 mg per administration.

13. Use according to any one of claims 1 to 12, wherein elafibranor, GFT1007, or a pharmaceutically acceptable salt of elafibranor or of GFT1007 is to be administered at a dose of 80 mg per administration.

14. Use according to any one of claims 1 to 13, wherein the subject having PBC has an inadequate response to ursodeoxycholic acid (UDCA).

15. Use according to any one of claims 1 to 14, wherein the pharmaceutical composition is to be administered in combination with an anti-cholestatic agent, preferably the other anti-cholestatic agent being ursodeoxycholic acid (UDCA).

16. Use according to any one of claims 1 to 15, wherein elafibanor is to be administered at a dose of 80 mg per administration in combination with ursodeoxycholic acid (UDCA).

17. Use according to claim 16, wherein the subject also has an inadequate response to ursodeoxycholic acid.